Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors from the central anxious program, conolidine modulates alternate molecular targets. A Science Advances study identified that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. By influ... https://maynardc826xgg5.wikicommunications.com/user